FDA label 2e925823-beb6-450b-adc9-78ec95bf76c6

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
90b40190-0f78-42fd-8ea4-5647db2f8f65
SPL ID
2e925823-beb6-450b-adc9-78ec95bf76c6
Version
2
Effective date
2011-06-01
Source export date
2026-10-12
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/ff22b88bd32e56cbc369af80345075227138a42b1b3ba9a84f038fd5493a7a47/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 02:06:00

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS Cardiovascular Effects. Tachycardia, arrhythmias and hypertension have been reported with ocular administration of epinephrine. Local Effects. The most frequent side effects reported with PROPINE ® alone were injection in 6.5% of patients and burning and stinging in 6%. Follicular conjunctivitis, eye pain, mydriasis, blurry vision, eye pruritus, headache and allergic reaction to PROPINE ® ophthalmic solution have been reported. Epinephrine therapy can lead to adrenochrome deposits in the conjunctiva and cornea.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.